Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Neuroblastoma 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Small Cell Lung Carcinoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Gliosarcoma 1Glioblastoma 1Carcinoma, Ovarian Epithelial 1Camurati-Engelmann Syndrome 1Burkitt Lymphoma 1Brain Neoplasms 1

Interventions

Docetaxel 26Prednisone 16Magnetic Resonance Spectroscopy 16Specimen Handling 15PROSTVAC 14Biopsy 12Goserelin 11bicalutamide 10Leuprolide 9sargramostim 8Estramustine 8Radiotherapy 7Lycopene 7High-Intensity Focused Ultrasound Ablation 7Flutamide 7Bevacizumab 7enzalutamide 6Thalidomide 6Mitoxantrone 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6ixabepilone 5olaparib 4cediranib 4Tomography, X-Ray Computed 4Radiation 4Nivolumab 4Magnetic Resonance Imaging 4Androgen Antagonists 4Amplified Fragment Length Polymorphism Analysis 4temsirolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Prostatic Neoplasms × Fenretinide × Clear all
NCT00080899 2015-03-06

Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 3 charts
Genitourinary

Prostatic Neoplasms

NCT00077402 2013-05-15

Fenretinide In Treating Patients With Advanced or Metastatic Hormone-Refractory Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Completed
50 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡